Revolutionizing Cancer Therapy With Transport Oncophysics
Our Mission Is to Be the First to Develop Fully Curative Approaches to Metastatic Cancer.
We are focused on developing drugs for the prevention, treatment, and cure of metastatic cancers using nanoporous silicon microparticles.
Unprecedented efficacy in treating metastatic cancer has been demonstrated in preclinical trials.
Our research has been published in leading peer-reviewed scientific journals.
Protected by strong patent portfolio with technology licensed from Houston Methodist Research Institute & University of Texas Health Science Center at Houston.
BrYet is a privately-owned biotech company focused on the discovery and development of novel physics-based, first-in-class therapies for metastatic liver and lung cancers.
Meet the expert team behind BrYet.
Learn more about our research and technology.
Catch up on the latest news and more from BrYet.
Reach out for more information.